Next Generation Sequencing (NGS) Markets 2015

LONDON, March 5, 2015 /PRNewswire/ -- No business planner in biotechnology or diagnostic equipment or services can ignore the trend of sequencing, and particularly next-generation sequencing. This technology has enabled a wide scope of research and genetic analysis. The promise of DNA sequencing has attracted many companies, researchers, and investors. DNA sequencing has already become a large market, and clinical applications of DNA sequencing are being developed and commercialized. More than ever, marketers of advanced equipment and those investing in those companies need a resource to identify the specific developments in sequencing.This report, Next-Generation Sequencing Markets (Systems, Consumables, Services, Acquisitions, Agreements, Competitive Analysis, Trends, Platforms, Applications, Brand Ownership) provides evidence of the promise and current excitement in the DNA sequencing market. Tracking the Path of Sequencing to the Clinical Lab Many improvements in sequencing technology are needed in order to make sequencing-based diagnostic tests widely available and used by all physicians, though DNA sequencing has successfully penetrated the research market. Applications of next generation sequencing in clinical laboratories and companies with CLIA-certified laboratories will continue to grow. The first next generation sequencing system and IVD tests have been cleared by the FDA, and more will follow. Some next generation sequencing companies are starting to develop and commercialize kits that can be produced and sold to clinical laboratories following the traditional in vitro diagnostic (IVD) model. Reasons for OptimismOver the years, the DNA sequencing field has gone through periods of excitement (referred to as hype) by some, followed by periods of disappointment as the hoped for advances have not materialized as quickly as hoped or promised. The promise of DNA sequencing has attracted many companies, researchers, investors, and others. DNA sequencing has already become a large market, and clinical applications of DNA sequencing are being developed and commercialized. Evidence of the promise and current excitement with DNA sequencing can be seen with many recent events:The DNA sequencing market is growing rapidly. In October 2014, market leader Illumina raised the company's full year 2014 guidance for investors to a revenue growth for the company of approximately 30% over the previous year. Roche and Foundation Medicine announced an agreement that is worth up to $1.2 billion. Roche agreed to acquire a majority interest in Foundation Medicine for approximately $780 million. Roche also agreed to invest $250 million in Foundation Medicine, and to fund potentially more than $150 million of R&D Companies are raising money: In just the first part of January 2015, In addition to Roche's investment in Foundation Medicine, 10X Genomics closed a $55.5 million Series B financing and Invitae filed for an initial public offering, These follow a busy 2014 year that saw many investments in next generation sequencing companies and companies with products or services related to next generation sequencing. Agreements with pharmaceutical companies: Companies in the pharmaceutical industry have recognized the potential benefits of next generation sequencing as a research and development tool. During just part of 2015, Genentech announced two agreements, and Pfizer announced one. Sequencing companies are starting to develop and commercialize kits that can be produced and sold to clinical laboratories following the traditional in vitro diagnostic (IVD) model. Illumina's MiSeqDx was the first cleared in vitro diagnostic (IVD) next generation sequencing system. MiSeqDx is also CE marked, and FDA-cleared tests are currently available on this platform. These are just selected highlights of recent activities in this rapidly changing market. Because of these trends, Kalorama expects the market to grow from its current size of 2.2 billion to 5.6 billion. The entire market is broken out in detail in Kalorama's Next Generation Sequencing Markets. This Informative Analysis Helps You Track These Developments, with Reliable Market Estimates The report provides the world markets for next generation sequencing in U.S. dollars for 2014 to 2018. As part of its analysis, the following data points are provided. DNA Sequencing Systems Market Size and Forecast DNA Sequencing Consumables Market, Size and Forecast DNA Sequencing Services Market, Size and Forecast Sequencing Market €" Geographical Distribution (US, Europe, Asia, ROW) Market Share by Major Competitor Brand Ownership by Platform DNA Sequencing Market €" Research versus Clinical Applications The sequencing market includes capillary electrophoresis sequencing systems (based on the early Sanger sequencing method) and also the rapidly growing next generation sequencing market. The market estimate includes both sequencing instruments plus consumables. Who's Doing What In Sequencing: Superior Company Profiling Competitor participation is an important part of the shaping of this market and the report devotes considerable detail to competitive analysis. Driven by the promise of clinical diagnostic applications, the DNA sequencing market is growing rapidly and companies are raising money. In early 2015 and throughout a busy 2014 there were many investments in next generation sequencing companies and companies with products or services related to next generation sequencing. Pharmaceutical companies, for example, have recognized the potential benefits of next generation sequencing as a research and development tool. The report provides product information and financial information for over 100 companies that are involved in next generation sequencing including: 10X Genomics 23andMe, Inc. Adaptive Biotechnologies Corporation Admera Health (A GENEWIZ Company) Advanced Biological Laboratories, S.A. Agilent Technologies Inc. AltheaDx Diagnostics, Inc. Ambry Genetics Corp. Aperiomics, Inc. Appistry, Inc. Asuragen, Inc. Athena Diagnostics, Inc. (A Quest Diagnostics Business) Base4 Innovation Ltd. Beckman Coulter, Inc. (Subsidiary of Danaher Corporation) BGI-Shenzhen Bina Technologies, Inc. (Acquired by Roche) BioDiscovery, Inc. Bioinnovation Solutions SA Biomatters Ltd. bioMerieux SA bioTheranostics (A bioMerieux Company) Cancer Genetics, Inc. CareDx, Inc. Caris Life Sciences Chronix Biomedical, Inc. CLC bio (A QIAGEN Company) Complete Genomics (A BGI Company) Courtagen Life Sciences, Inc. Cypher Genomics, Inc. DioGenix, Inc. DNA Electronics Ltd. DNASTAR, Inc. Eurofins Genomics Eurofins MWG Operon Inc. (A Eurofins Genomics Company) Expression Analysis, Inc. (A Quintiles Company) Fluidigm Corporation Foundation Medicine, Inc. GATC Biotech AG GenapSys GenDx Gene by Gene, Ltd. Genection, Inc. (An Invivoscribe Company) GeneDx GeneInsight, Inc. GENEWIZ Inc. Genia Technologies, Inc. (Acquired by Roche) GenoLogics Life Sciences Software Genomic Diagnostics Technologies GenomOncology Genoptix (A Novartis Company) GigaGen, Inc. GnuBIO, Inc. (Acquired by Bio-Rad Laboratories, Inc.) Good Start Genetics, Inc. HTG Molecular Diagnostics Human Longevity, Inc. Igenbio, Inc. Illumina, Inc. Innovations Exchange Pte Ltd (INEX) iGene„¢ Diagnostics Pte Ltd (an INEX Company) Insight Genetics, Inc. InSilixa, Inc. Intel Corporation Intelligent Bio-Systems, Inc. (A QIAGEN Company) Invivoscribe Technologies, Inc. iRepertoire, Inc. Knome Inc. Laboratory Corporation of America (LabCorp) LaserGen, Inc. LifeCodexx AG (Subsidiary of GATC Biotech AG) Life Technologies Corporation (Acquired by Thermo Fischer Scientific Inc.) Mayo Medical Laboratories and Mayo Clinic MolecularMD Corporation Multiplicom NV Nabsys, Inc. Natera, Inc. NeoGenomics, Inc./NeoGenomics Laboratories NetBio, Inc. NewGene Ltd. NextCODE Health NobleGen Biosciences, Inc. N-of-One, Inc. OncoDNA SA OncoPlex Diagnostics (OncoPlexDx) Oncospire Genomics One Lambda, Inc. (A Thermo Fisher Scientific Brand) Oxford Gene Technology Oxford Nanopore Technologies Ltd. Pacific Biosciences Parabase Genomics Pathway Genomics Corporation PerkinElmer, Inc. Personal Genome Diagnostics, Inc. Personalis, Inc. PicoSeq Population Genetics Technologies Ltd. QIAGEN N.V. QuantuMDx Group Quest Diagnostics RainDance Technologies, Inc. Response Genetics, Inc. Roche SeqLL, LLC Sequenta, Inc. Siemens Healthcare Diagnostics Siemens Sirona Genomics SoftGenetics, LLC Stratos Genomics Inc. Swift Biosciences, Inc. Symbiodx Sysmex Inostics GmbH Thermo Fisher Scientific, Inc. Vela Diagnostics WaferGen Biosystems, Inc. ZS Genetics, Inc. The information presented in this report is derived from publicly available information sources such as company reports and announcements, government reports and databases, medical organization reports, medical associations, and other publications. The analysis is based on the author's industry knowledge combined with literature searches and discussions with industry professionals and experts in the areas of point-of-care tests, decentralized healthcare and healthcare economics. Download the full report: https://www.reportbuyer.com/product/2736754/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.com

Advertisement

For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected]  Tel: +44 208 816 85 48 Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/next-generation-sequencing-ngs-markets-2015-300046436.html

SOURCE ReportBuyer